Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-DLL3/DLL3/CD3 trispecific antibody ZG006

A trispecific T-cell engaging (TCE) antibody directed against two different epitopes of the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-DLL3/DLL3/CD3 trispecific antibody ZG006 binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and the DLL3 antigen on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:DLL3 x DLL3 x CD3 trispecific antibody ZG006
T-cell engaging antibody ZG006
TCE antibody ZG006
Code name:ZG 006
ZG-006
ZG006
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search